GSK Annual Report 2002

Description of business
GlaxoSmithKline 05
The Description of business discusses the activities, the
resources and the operating environment of the business and
identifies developments and achievements in 2002, under the
following headings:
The business
06 History and development of the company
07 Products
Operating environment
10 Competition
11 Regulation
Operating activities
13 Marketing and distribution
13 Manufacture and supply
14 Research and development
Operating resources
23 Intellectual property
24 Information technology
24 GlaxoSmithKline people
25 Property, plant and equipment
The business and the community
26 Corporate and social responsibility
26 Responsibility for environment, health and safety
27 Access to healthcare in the developing world
27 Global community partnerships
Discussion of the Group’s management structures and corporate
governance procedures is set out in Corporate governance
(pages 31 to 38).
The Remuneration report gives details of the Group’s policies on
Directors’ remuneration and the amounts earned by Directors
and senior management in 2002 (pages 39 to 50).
Discussion of the Group’s operating and financial performance
and financial resources is given in the Operating and financial
review and prospects (pages 51 to 72).
In this report: ‘GlaxoSmithKline’ or the ‘Group’ means GlaxoSmithKline
plc and its subsidiary undertakings and the ‘company’ means
GlaxoSmithKline plc; ‘GlaxoSmithKline share’ means an Ordinary Share
of GlaxoSmithKline plc of 25p. American Depositary Shares (ADS)
represent two GlaxoSmithKline shares.
Throughout this report, figures quoted for market size, market share
and market growth rates relate to the 12 months ended 30th
September 2002 (or later where available). These are GlaxoSmithKline
estimates based on the most recent data from independent external
sources, valued in sterling at relevant exchange rates. Figures quoted
for product market share reflect sales by GlaxoSmithKline and licensees.
Brand names appearing in italics throughout this report are trade marks
of GlaxoSmithKline or associated companies, with the exception of
Baycol and Levitra, trade marks of Bayer AG, Bexxar, a trade mark of
Corixa Corporation, Inc, Hepsera, a trademark of Gilead Services, Inc,
Natrecor, a trade mark of Scios Inc, Navelbine, a trade mark of Pierre
Fabre Médicament, Nicoderm, a trade mark of Aventis SA and Pritor, a
trade mark of Boehringer Ingelheim International GmbH, all of which
are used under licence by the Group.